Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

BCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single B...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2016-02, Vol.127 (6), p.703-712
Hauptverfasser:	Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., Branford, Susan
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Substitution Chemotherapy, Adjuvant Clinical Trials and Observations DNA Mutational Analysis - methods Drug Resistance, Neoplasm - genetics Fusion Proteins, bcr-abl - genetics High-Throughput Nucleotide Sequencing Humans Imidazoles - therapeutic use Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - genetics Mutation - physiology Neoadjuvant Therapy Protein Kinase Inhibitors - therapeutic use Pyridazines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!